A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Rheumatoid Arthritis

Condition studied

Rheumatoid Arthritis

Investigational medicinal product(s)

Eligibility

Primary endpoint

Proportion of Participants Achieving American College of Rheumatology 20% Response Criteria (ACR20) at Week 12

Endpoint detail

Proportion of Participants Achieving American College of Rheumatology 50% Response Criteria (ACR50) at Week 12, Proportion of Participants Achieving American College of Rheumatology 70% Response Criteria (ACR70) at Week 12, Proportion of Participants Achieving Low Disease Activity (LDA) based on Disease Activity Score 28 Using C-Reactive Protein (DAS28-CRP), Change From Baseline in the Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Week 12, Number of Participants Who Experience One or More Adverse Events (AEs), Number of Participants Who Discontinue Study Intervention Due to an AE